This page brings together the Agency's latest information on diabetes. It lists:
Forxiga is a medicine used in adults for treating: diabetes in patients whose condition is not controlled well enough. In type 2 diabetes, it is used with appropriate diet and exercise in patients...
Suliqua is a medicine that is used together with metformin (another diabetes medicine), with or without SGLT-2 inhibitors (other diabetes medicines), for the treatment of adults with type 2 diabetes...
Steglujan is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes. It is used together with diet and exercise in the following patients: patients whose blood glucose...
Edistride is a medicine used in adults with type 2 diabetes whose condition is not controlled well enough. It is used with appropriate diet and exercise in patients who cannot take metformin (another...
This is a summary of the European public assessment report (EPAR) for Insuman. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
Fifteen new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting. The Committee recommended granting a marketing authorisation for Givlaari* (givosiran), the...
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorization in the European Union (EU) for Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control...
EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. This medicine is already approved...
EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus. Dapagliflozin is already authorised in the European Union as...
Diabetes patients reminded of importance of preventative foot care The European Medicines Agency (EMA) is informing about a potential increased risk of lower limb amputation (mostly affecting the toes) in patients taking the SGLT2 inhibitors...
Recommendations for patients with kidney impairment updated in product information The European Medicines Agency (EMA) has concluded that metformin-containing medicines can now be used in patients with moderately reduced kidney function (GFR [...